Pfizer Inc. (PFE) — closed signal from January 1, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on April 1, 2026.
Predicted vs. what happened
What happened
Reached its target in 41 days.
The thesis — published January 1, 2026
Pfizer looks like it's bouncing after a sharp selloff, and its dividend and recent headlines about modest price increases could make some buyers return. The stock is very oversold, so a short-term recovery is possible, but underlying trend remains weak and the rally might not hold. Treat this as a short-term, tight-risk trade over the next 0-3 months.
Primary drivers
- Very oversold can create quick bounce opportunities
- Dividend focus can draw safety-oriented buyers
- Small price hikes can improve investor mood short-term
- Recovery relies on improving buying momentum, not value change
How it played out
PFE: target reached in 41 days
Lyra published PFE at $24.90 on 2026-01-01, with a short-term window through 2026-04-01. The thesis expected 12% growth. It pointed to an oversold setup after a sharp selloff, dividend-focused buyers, modest price increases, and the need for better buying momentum.
Inside the window, PFE reached the $27.89 target in 41 days. The stock peaked at $28.64 on 2026-04-01, with a 15% peak gain. It ended at $28.55. The published bounce thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.